US226A
(en)
|
|
1837-06-03 |
|
Samuel goss |
US541606A
(en)
|
|
1895-06-25 |
|
Sealed package |
US7709A
(en)
|
|
1850-10-08 |
Chas S Gaylord |
Improved spring-grapple
|
GB2116183B
(en)
|
1982-03-03 |
1985-06-05 |
Genentech Inc |
Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
US4978672A
(en)
|
1986-03-07 |
1990-12-18 |
Ciba-Geigy Corporation |
Alpha-heterocyclc substituted tolunitriles
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
WO1988001649A1
(en)
|
1986-09-02 |
1988-03-10 |
Genex Corporation |
Single polypeptide chain binding molecules
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
ATE95193T1
(de)
|
1987-06-17 |
1993-10-15 |
Sandoz Ag |
Cyclosporine und deren benutzung als arzneimittel.
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
US6362325B1
(en)
|
1988-11-07 |
2002-03-26 |
Advanced Research And Technology Institute, Inc. |
Murine 4-1BB gene
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
US6582959B2
(en)
|
1991-03-29 |
2003-06-24 |
Genentech, Inc. |
Antibodies to vascular endothelial cell growth factor
|
US20030206899A1
(en)
|
1991-03-29 |
2003-11-06 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists
|
JP4124480B2
(ja)
|
1991-06-14 |
2008-07-23 |
ジェネンテック・インコーポレーテッド |
免疫グロブリン変異体
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
DE69233745D1
(de)
|
1991-12-02 |
2008-10-23 |
Cambridge Antibody Tech |
Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
|
DE69233803D1
(de)
|
1992-10-28 |
2011-03-31 |
Genentech Inc |
Verwendung von vaskulären Endothelwachstumsfaktor-Antagonisten
|
RO118524B1
(ro)
|
1992-11-13 |
2003-06-30 |
Idec Pharmaceuticals Corp San |
Metoda pentru tratarea unei tulburari legata de celulele b
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
CA2150262C
(en)
|
1992-12-04 |
2008-07-08 |
Kaspar-Philipp Holliger |
Multivalent and multispecific binding proteins, their manufacture and use
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
US7138500B1
(en)
|
1993-05-07 |
2006-11-21 |
Immunex Corporation |
Antibodies to human 4-1BB
|
IL108501A
(en)
|
1994-01-31 |
1998-10-30 |
Mor Research Applic Ltd |
Antibodies and pharmaceutical compositions containing them
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
US5688690A
(en)
|
1994-09-16 |
1997-11-18 |
The Wistar Institute Of Anatomy And Biology |
Human cytotoxic lymphocyte signal transduction surface protein (P38) and monoclonal antibodies thereto
|
IL117645A
(en)
|
1995-03-30 |
2005-08-31 |
Genentech Inc |
Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
|
AUPO591797A0
(en)
|
1997-03-27 |
1997-04-24 |
Commonwealth Scientific And Industrial Research Organisation |
High avidity polyvalent and polyspecific reagents
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
AU690474B2
(en)
*
|
1995-09-11 |
1998-04-23 |
Kyowa Hakko Kirin Co., Ltd. |
Antibody againts alpha-chain of human interleukin 5 receptor
|
JP2002514895A
(ja)
*
|
1995-09-28 |
2002-05-21 |
アレクション、ファーマスーティカルズ、インコーポレーテッド |
ブタ細胞相互作用タンパク質
|
US7357927B2
(en)
|
1996-03-12 |
2008-04-15 |
Human Genome Sciences, Inc. |
Death domain containing receptors
|
AU4055697A
(en)
|
1996-08-16 |
1998-03-06 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
US6140076A
(en)
|
1996-12-06 |
2000-10-31 |
Schering Corporation |
Ig superfamily `dlair` receptors expressed in monocytes
|
US20060280140A9
(en)
*
|
1997-02-06 |
2006-12-14 |
Mahany Ronald L |
LOWER POWER WIRELESS BEACONING NETWORK SUPPORTING PROXIMAL FORMATION, SEPARATION AND REFORMATION OF WIRELESS LOCAL AREA NETWORKS (LAN's), AS TERMINALS MOVE IN AND OUT RANGE OF ONE ANOTHER
|
US6972323B1
(en)
|
1997-04-01 |
2005-12-06 |
Sankyo Company, Limited |
Anti-Fas antibodies
|
US6884879B1
(en)
|
1997-04-07 |
2005-04-26 |
Genentech, Inc. |
Anti-VEGF antibodies
|
NZ500077A
(en)
|
1997-04-07 |
2001-10-26 |
Genentech Inc |
Humanized antibodies to vascular endothelial growth factor (VEGF) and methods for their preparation.
|
BRPI9809387B8
(pt)
|
1997-04-07 |
2021-05-25 |
Genentech Inc |
anticorpo humanizado anti-fator de crescimento endotelial vascular humano e composição que o compreende
|
US20020032315A1
(en)
|
1997-08-06 |
2002-03-14 |
Manuel Baca |
Anti-vegf antibodies
|
EP0983303B1
(en)
|
1997-05-21 |
2006-03-08 |
Biovation Limited |
Method for the production of non-immunogenic proteins
|
CO4940418A1
(es)
|
1997-07-18 |
2000-07-24 |
Novartis Ag |
Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
|
WO1999014353A2
(en)
|
1997-09-19 |
1999-03-25 |
Dana-Farber Cancer Institute, Inc. |
Intrabody-mediated control of immune reactions
|
GB9722131D0
(en)
*
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
AU1102399A
(en)
|
1997-10-21 |
1999-05-10 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
|
EP1053321A1
(en)
|
1998-02-09 |
2000-11-22 |
Genentech, Inc. |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
DE19835635C2
(de)
|
1998-08-06 |
2000-05-25 |
Knorr Bremse Systeme |
Relaisventil für Druckluftbremssysteme von Schienenfahrzeugen
|
US6818749B1
(en)
|
1998-10-31 |
2004-11-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Variants of humanized anti carcinoma monoclonal antibody cc49
|
US7888477B2
(en)
|
1998-12-17 |
2011-02-15 |
Corixa Corporation |
Ovarian cancer-associated antibodies and kits
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6703020B1
(en)
|
1999-04-28 |
2004-03-09 |
Board Of Regents, The University Of Texas System |
Antibody conjugate methods for selectively inhibiting VEGF
|
WO2001003720A2
(en)
|
1999-07-12 |
2001-01-18 |
Genentech, Inc. |
Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
|
ES2539411T3
(es)
|
1999-08-23 |
2015-06-30 |
Dana-Farber Cancer Institute, Inc. |
PD-1, receptor para la B7-4 y su utilización
|
JP2003531821A
(ja)
|
1999-12-29 |
2003-10-28 |
イムノージェン インコーポレーテッド |
改変型ドキソルビシンおよびダウノルビシンを含む細胞傷害性薬剤ならびにその治療上の使用
|
GB0018891D0
(en)
|
2000-08-01 |
2000-09-20 |
Novartis Ag |
Organic compounds
|
MXPA02007473A
(es)
|
2000-02-01 |
2003-09-22 |
Tanox Inc |
Moleculas activadoras de celulas presentadoras de antigenos (apc) que se unen a cd40.
|
AU2001259215A1
(en)
|
2000-04-28 |
2001-11-12 |
La Jolla Institute For Allergy And Immunology |
Human anti-cd40 antibodies and methods of making and using same
|
US6696620B2
(en)
|
2000-05-02 |
2004-02-24 |
Epicyte Pharmaceutical, Inc. |
Immunoglobulin binding protein arrays in eukaryotic cells
|
MXPA02012106A
(es)
|
2000-06-06 |
2003-06-06 |
Bristol Myers Squibb Co |
Polipeptidos y acidos nucleicos relacionados con b7 empleados para inmunomodulacion.
|
NZ523105A
(en)
|
2000-06-22 |
2004-07-30 |
Genentech Inc |
Agonist anti-trk-C monoclonal antibodies
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
CN1487996B
(zh)
|
2000-11-30 |
2010-06-16 |
米德列斯公司 |
用于生产人类抗体的转基因转染色体啮齿动物
|
EP1355948B1
(en)
|
2001-01-12 |
2009-03-11 |
Molecules of Man AB |
Materials and methods for treatment of hepatitis c
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
US7667004B2
(en)
|
2001-04-17 |
2010-02-23 |
Abmaxis, Inc. |
Humanized antibodies against vascular endothelial growth factor
|
EP1539233B1
(en)
|
2001-07-12 |
2011-04-27 |
FOOTE, Jefferson |
Super humanized antibodies
|
US20030226155A1
(en)
|
2001-08-30 |
2003-12-04 |
Biorexis Pharmaceutical Corporation |
Modified transferrin-antibody fusion proteins
|
US20040142325A1
(en)
*
|
2001-09-14 |
2004-07-22 |
Liat Mintz |
Methods and systems for annotating biomolecular sequences
|
ATE335490T1
(de)
|
2001-10-30 |
2006-09-15 |
Novartis Pharma Gmbh |
Staurosporin-derivate als hemmer der flt3- rezeptor-tyrosinkinase-wirkung
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
ES2485841T3
(es)
|
2002-02-01 |
2014-08-14 |
Ariad Pharmaceuticals, Inc |
Compuestos que contienen fósforo y usos de los mismos
|
PT3000810T
(pt)
|
2002-03-13 |
2017-10-25 |
Array Biopharma Inc |
Derivados de benzimidazole alquilado n3 como inibidores de mek
|
EP1525223B1
(en)
|
2002-06-13 |
2007-11-21 |
Crucell Holland B.V. |
Ox40 (=cd134) receptor agonists and therapeutic use
|
WO2007001459A2
(en)
|
2004-11-15 |
2007-01-04 |
Washington University |
Compositions and methods for modulating lymphocyte activity
|
US8546541B2
(en)
|
2002-06-20 |
2013-10-01 |
Washington University |
Compositions and methods for modulating lymphocyte activity
|
EP3287144A1
(en)
|
2002-07-03 |
2018-02-28 |
ONO Pharmaceutical Co., Ltd. |
Immunopotentiating compositions
|
GB0215676D0
(en)
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
US20040047858A1
(en)
|
2002-09-11 |
2004-03-11 |
Blumberg Richard S. |
Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
|
EP1560593B1
(en)
|
2002-10-25 |
2016-04-20 |
Genentech, Inc. |
Novel composition and methods for the treatment of immune related diseases
|
EP2287192B1
(en)
|
2002-11-15 |
2015-08-26 |
Novartis Vaccines and Diagnostics, Inc. |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
BRPI0407403B1
(pt)
|
2003-02-11 |
2022-07-19 |
Cancer Research Technology Ltd |
Compostos de isoxazol e composição farmacêutica
|
MXPA05008521A
(es)
*
|
2003-02-13 |
2005-10-20 |
Pharmacia Corp |
Anticuerpos a c-met para el tratamiento de canceres.
|
US20070048740A1
(en)
|
2003-02-14 |
2007-03-01 |
Research Association For Biotechnology |
Full-length cDNA
|
WO2005035732A2
(en)
|
2003-02-19 |
2005-04-21 |
Dyax Corporation |
Papp-a ligands
|
ES2330224T3
(es)
*
|
2003-04-17 |
2009-12-07 |
Cytec Technology Corp. |
Composicion y proceso para la extraccion de metales con disolvente usando agentes de extraccion de aldoxima o cetoxima.
|
US20050025763A1
(en)
|
2003-05-08 |
2005-02-03 |
Protein Design Laboratories, Inc. |
Therapeutic use of anti-CS1 antibodies
|
NZ543654A
(en)
|
2003-05-23 |
2009-05-31 |
Wyeth Corp |
GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
|
ME00425B
(me)
|
2003-05-30 |
2011-10-10 |
Genentech Inc |
Liječenje sa anti-vegf antitijelima
|
KR101420344B1
(ko)
*
|
2003-07-02 |
2014-07-16 |
위니베르시따 디 제노바 |
Pan-kir2dl nk-수용체 항체 및 진단 및 치료에서의 그 사용 방법
|
US20050048054A1
(en)
|
2003-07-11 |
2005-03-03 |
Shino Hanabuchi |
Lymphocytes; methods
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
US7758859B2
(en)
|
2003-08-01 |
2010-07-20 |
Genentech, Inc. |
Anti-VEGF antibodies
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
EP1682103A1
(en)
|
2003-10-27 |
2006-07-26 |
Novartis AG |
Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation
|
KR101192496B1
(ko)
|
2003-11-06 |
2012-10-18 |
시애틀 지네틱스, 인크. |
리간드에 접합될 수 있는 모노메틸발린 화합물
|
CA2545166A1
(en)
|
2003-11-11 |
2005-05-19 |
Chugai Seiyaku Kabushiki Kaisha |
Humanized anti-cd47 antibody
|
UY28641A1
(es)
*
|
2003-11-28 |
2005-06-30 |
Astrazeneca Ab |
Anticuerpos
|
EP1692318A4
(en)
|
2003-12-02 |
2008-04-02 |
Genzyme Corp |
COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER
|
AU2005207946A1
(en)
|
2004-01-23 |
2005-08-11 |
Amgen Inc. |
Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
|
US7973139B2
(en)
*
|
2004-03-26 |
2011-07-05 |
Human Genome Sciences, Inc. |
Antibodies against nogo receptor
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
CN101031569B
(zh)
|
2004-05-13 |
2011-06-22 |
艾科斯有限公司 |
作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
|
US20060002932A1
(en)
|
2004-06-04 |
2006-01-05 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
PL1761528T3
(pl)
|
2004-06-11 |
2008-05-30 |
Japan Tobacco Inc |
Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-D]pirymidyny i związki pokrewne do leczenia raka
|
US7378423B2
(en)
|
2004-06-11 |
2008-05-27 |
Japan Tobacco Inc. |
Pyrimidine compound and medical use thereof
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
US20060009360A1
(en)
|
2004-06-25 |
2006-01-12 |
Robert Pifer |
New adjuvant composition
|
US20060099203A1
(en)
|
2004-11-05 |
2006-05-11 |
Pease Larry R |
B7-DC binding antibody
|
CA2577082A1
(en)
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
CA2586313C
(en)
|
2004-11-10 |
2016-03-08 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
MX2007008256A
(es)
*
|
2005-01-07 |
2007-12-06 |
Lexicon Pharmaceuticals Inc |
Anticuerpos monoclonales contra proteina 4 similar a angiopoyetina (angptl4).
|
WO2006096527A2
(en)
|
2005-03-04 |
2006-09-14 |
Diversa Corporation |
Nucleic acids and proteins and methods for making and using them
|
EP2386638A3
(en)
|
2005-03-25 |
2012-08-15 |
National Research Council Of Canada |
Method for isolation of soluble polypeptides
|
ES2657443T3
(es)
|
2005-03-25 |
2018-03-05 |
Gitr, Inc. |
Anticuerpos anti-GITR y usos de los mismos
|
JP5620626B2
(ja)
|
2005-03-31 |
2014-11-05 |
中外製薬株式会社 |
会合制御によるポリペプチド製造方法
|
PL2439273T3
(pl)
|
2005-05-09 |
2019-08-30 |
Ono Pharmaceutical Co., Ltd. |
Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami
|
SI1879573T1
(sl)
|
2005-05-10 |
2013-04-30 |
Incyte Corporation Experimental Station |
Modulatorji indolamin 2,3-dioksigenaze in postopki za uporabo le-te
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
KR100991010B1
(ko)
|
2005-05-26 |
2010-10-29 |
제넨테크, 인크. |
인간화 항-cd40 항체 및 그의 사용 방법
|
PL1907000T5
(pl)
|
2005-06-08 |
2020-11-16 |
Dana-Farber Cancer Institute |
Metody i kompozycje do leczenia infekcji przetrwałych
|
JP2006345852A
(ja)
*
|
2005-06-16 |
2006-12-28 |
Virxsys Corp |
抗体複合体
|
DE102005028778A1
(de)
|
2005-06-22 |
2006-12-28 |
SUNJÜT Deutschland GmbH |
Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
|
JP4557003B2
(ja)
|
2005-07-01 |
2010-10-06 |
株式会社村田製作所 |
多層セラミック基板およびその製造方法ならびに多層セラミック基板作製用複合グリーンシート
|
RS54271B1
(en)
|
2005-07-01 |
2016-02-29 |
E. R. Squibb & Sons, L.L.C. |
HUMAN MONOCLONIC ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1)
|
BRPI0614040B8
(pt)
|
2005-07-18 |
2021-05-25 |
Amgen Inc |
anticorpo isolado que se liga especificamente a b7rp1, polipeptídeo, composição farmacêutica, vetor de expressão, célula hospedeira, linhagem celular isolada e métodos para a detecção de b7rp1 em uma amostra biológica e de produção de um anticorpo ou polipeptídeo
|
PE20070335A1
(es)
|
2005-08-30 |
2007-04-21 |
Novartis Ag |
Benzimidazoles sustituidos y metodos para su preparacion
|
SG10201402712QA
(en)
*
|
2005-08-31 |
2014-08-28 |
Merck Sharp & Dohme |
Engineered anti-il-23 antibodies
|
EP1963371A2
(en)
|
2005-12-08 |
2008-09-03 |
Medarex Inc. |
Human monoclonal antibodies to o8e
|
DK2348023T5
(da)
|
2005-12-13 |
2017-05-15 |
Incyte Holdings Corp |
Heteroaryl-substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus-kinase-inhibitorer
|
US20110212086A1
(en)
|
2006-01-19 |
2011-09-01 |
Genzyme Corporation |
GITR Antibodies For The Treatment of Cancer
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
WO2007095337A2
(en)
|
2006-02-15 |
2007-08-23 |
Imclone Systems Incorporated |
Antibody formulation
|
CA2646965C
(en)
|
2006-03-24 |
2016-06-21 |
Jonathan H. Davis |
Engineered heterodimeric protein domains
|
UA93548C2
(uk)
|
2006-05-05 |
2011-02-25 |
Айерем Елелсі |
Сполуки та композиції як модулятори хеджхогівського сигнального шляху
|
EP2035456A1
(en)
|
2006-06-22 |
2009-03-18 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
PE20110220A1
(es)
|
2006-08-02 |
2011-04-11 |
Novartis Ag |
DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
|
TW201441262A
(zh)
|
2006-08-18 |
2014-11-01 |
Novartis Ag |
催乳激素受體(prlr)之專一性抗體及其用途
|
ATE531720T1
(de)
|
2006-08-21 |
2011-11-15 |
Genentech Inc |
Aza-benzofuranylverbindungen und anwendungsverfahren dafür
|
MX2009002694A
(es)
*
|
2006-09-29 |
2009-03-24 |
Hoffmann La Roche |
Anticuerpos dirigidos contra ccr5 y usos de los mismos.
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
WO2008076560A2
(en)
|
2006-11-15 |
2008-06-26 |
Medarex, Inc. |
Human monoclonal antibodies to btla and methods of use
|
CN103641833A
(zh)
|
2006-12-08 |
2014-03-19 |
Irm责任有限公司 |
作为蛋白激酶抑制剂的化合物和组合物
|
US20080226635A1
(en)
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
EP2124998B8
(en)
|
2006-12-27 |
2015-05-06 |
The Johns Hopkins University |
Methods for detecting inflammation and auto-immune diseases
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
EP2170959B1
(en)
|
2007-06-18 |
2013-10-02 |
Merck Sharp & Dohme B.V. |
Antibodies to human programmed death receptor pd-1
|
ES2776406T3
(es)
|
2007-07-12 |
2020-07-30 |
Gitr Inc |
Terapias de combinación que emplean moléculas de enlazamiento a GITR
|
KR20100058509A
(ko)
|
2007-07-31 |
2010-06-03 |
메디뮨 엘엘씨 |
다중특이적 에피토프 결합 단백질 및 이의 용도
|
WO2009024531A1
(en)
|
2007-08-17 |
2009-02-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method for treating and diagnosing hematologic malignancies
|
US8748356B2
(en)
|
2007-10-19 |
2014-06-10 |
Janssen Biotech, Inc. |
Methods for use in human-adapting monoclonal antibodies
|
WO2009056509A1
(en)
|
2007-11-02 |
2009-05-07 |
Novartis Ag |
Improved nogo-a binding molecules and pharmaceutical use thereof
|
SI2594590T1
(sl)
|
2007-12-14 |
2015-03-31 |
Bristol-Myers Squibb Company |
Postopek za izdelavo vezavnih molekul za humani receptor OX40
|
PE20091158A1
(es)
|
2007-12-19 |
2009-08-28 |
Genentech Inc |
5-anilinoimidazopiridinas y metodos de uso
|
JP2011507519A
(ja)
|
2007-12-19 |
2011-03-10 |
セントコア・オーソ・バイオテツク・インコーポレーテツド |
pIX又はpVIIへの融合を介したヒトデノボpIXファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
WO2009114870A2
(en)
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
AR070924A1
(es)
|
2008-03-19 |
2010-05-12 |
Novartis Ag |
Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
|
FR2929946B1
(fr)
|
2008-04-11 |
2010-05-28 |
Pf Medicament |
Nouveaux anticorps anti-cd151 et leur utilisation pour le traitement du cancer
|
WO2009134389A2
(en)
|
2008-05-01 |
2009-11-05 |
Gtc Biotherapeutics, Inc. |
An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
|
UY31929A
(es)
|
2008-06-25 |
2010-01-05 |
Irm Llc |
Compuestos y composiciones como inhibidores de cinasa
|
JP2011526794A
(ja)
|
2008-07-02 |
2011-10-20 |
エマージェント プロダクト デベロップメント シアトル, エルエルシー |
TGF−βアンタゴニスト多重標的結合性分子
|
BRPI0915231A2
(pt)
|
2008-07-08 |
2018-06-12 |
Intellikine Inc |
compostos inibidores de quinase e métodos de uso
|
US20100041663A1
(en)
|
2008-07-18 |
2010-02-18 |
Novartis Ag |
Organic Compounds as Smo Inhibitors
|
US9273136B2
(en)
|
2008-08-04 |
2016-03-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fully human anti-human NKG2D monoclonal antibodies
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
PL2331547T3
(pl)
|
2008-08-22 |
2015-01-30 |
Novartis Ag |
Związki pirolopirymidynowe jako inhibitory CDK
|
BRPI0918268B1
(pt)
|
2008-09-02 |
2021-08-03 |
Novartis Ag |
Derivados de picolinamida, seu uso, e composição farmacêutica
|
UA104147C2
(uk)
|
2008-09-10 |
2014-01-10 |
Новартис Аг |
Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
|
AU2009290544B2
(en)
|
2008-09-12 |
2015-07-16 |
Oxford University Innovation Limited |
PD-1 specific antibodies and uses thereof
|
EP2342228B1
(en)
|
2008-09-12 |
2017-09-06 |
Oxford University Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
US8586023B2
(en)
|
2008-09-12 |
2013-11-19 |
Mie University |
Cell capable of expressing exogenous GITR ligand
|
JP5731978B2
(ja)
|
2008-09-26 |
2015-06-10 |
インテリカイン, エルエルシー |
複素環キナーゼ阻害剤
|
AU2009296392B2
(en)
|
2008-09-26 |
2016-06-02 |
Dana-Farber Cancer Institute, Inc. |
Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
|
KR101050829B1
(ko)
|
2008-10-02 |
2011-07-20 |
서울대학교산학협력단 |
항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제
|
US20100261620A1
(en)
|
2008-10-14 |
2010-10-14 |
Juan Carlos Almagro |
Methods of Humanizing and Affinity-Maturing Antibodies
|
JO3096B1
(ar)
*
|
2008-11-07 |
2017-03-15 |
Imclone Llc |
الأجسام المضادة لمستقبل ii مضاد tgfb
|
PL2370076T3
(pl)
|
2008-11-28 |
2017-06-30 |
Novartis Ag |
Kombinacja farmaceutyczna zawierająca inhibitor Hsp 90 i inhibitor mTOR
|
CN114835812A
(zh)
|
2008-12-09 |
2022-08-02 |
霍夫曼-拉罗奇有限公司 |
抗-pd-l1抗体及它们用于增强t细胞功能的用途
|
WO2010078580A2
(en)
|
2009-01-05 |
2010-07-08 |
The Johns Hopkins University |
Immunotherapy for contact dermatitis using co-signal regulation
|
US20120017292A1
(en)
|
2009-01-16 |
2012-01-19 |
Kovalic David K |
Isolated novel nucleic acid and protein molecules from corn and methods of using those molecules to generate transgene plants with enhanced agronomic traits
|
EP2210903A1
(en)
|
2009-01-21 |
2010-07-28 |
Monoclonal Antibodies Therapeutics |
Anti-CD160 monoclonal antibodies and uses thereof
|
ES2629337T3
(es)
|
2009-02-09 |
2017-08-08 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
|
UA103918C2
(en)
|
2009-03-02 |
2013-12-10 |
Айерем Элелси |
N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
|
AR075989A1
(es)
*
|
2009-04-10 |
2011-05-11 |
Lilly Co Eli |
Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
|
WO2010129304A2
(en)
|
2009-04-27 |
2010-11-11 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
CN102482354B
(zh)
|
2009-04-30 |
2015-02-25 |
特尔汗什莫尔医学基础设施研究和服务公司 |
抗ceacam1抗体以及使用该抗体的方法
|
RU2420587C2
(ru)
*
|
2009-06-25 |
2011-06-10 |
Открытое акционерное общество "Всероссийский научный Центр молекулярной диагностики и лечения" (ОАО ВНЦМДЛ) |
ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА И Fab, СВЯЗЫВАЮЩИЕСЯ С АНТИГЕНОМ F1 ИЗ Yersinia pestis, И СПОСОБ ИХ ПОЛУЧЕНИЯ С ИСПОЛЬЗОВАНИЕМ ДРОЖЖЕЙ
|
UA105794C2
(uk)
|
2009-06-26 |
2014-06-25 |
Новартіс Аг |
1,3-ДИЗАМІЩЕНІ ПОХІДНІ ІМІДАЗОЛІДИН-2-ОНУ ЯК ІНГІБІТОРИ Cyp17
|
MX2012001417A
(es)
|
2009-07-31 |
2012-07-03 |
Organon Nv |
Anticuerpos completamente humanos para atenuante de linfocitos b y t (btla).
|
JO3002B1
(ar)
|
2009-08-28 |
2016-09-05 |
Irm Llc |
مركبات و تركيبات كمثبطات كيناز بروتين
|
IN2012DN01920A
(es)
|
2009-09-03 |
2015-07-24 |
Schering Corp |
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
LT3279215T
(lt)
|
2009-11-24 |
2020-04-10 |
Medimmune Limited |
Tiksliniai surišantys agentai prieš b7-h1
|
ES2609043T3
(es)
|
2009-11-30 |
2017-04-18 |
Janssen Biotech, Inc. |
Anticuerpos mutantes Fc con funciones de efecto abladas
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
PT2519543T
(pt)
|
2009-12-29 |
2016-10-07 |
Emergent Product Dev Seattle |
Proteínas de ligação de heterodímero e suas utilizações
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
CA2790200A1
(en)
*
|
2010-02-19 |
2011-08-25 |
The Board Of Regents Of The University Of Oklahoma |
Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
|
ME03447B
(me)
|
2010-03-04 |
2020-01-20 |
Macrogenics Inc |
Anтitela reakтivna sa b7-нз, njihovi imunološki akтivni fragmenтi i upotreba
|
CA2791930A1
(en)
|
2010-03-11 |
2011-09-15 |
Kerry Louise Tyson |
Pd-1 antibody
|
CN103097417B
(zh)
|
2010-04-20 |
2019-04-09 |
根马布股份公司 |
含异二聚体抗体fc的蛋白及其制备方法
|
WO2011139973A2
(en)
*
|
2010-05-03 |
2011-11-10 |
Abbott Laboratories |
Methods of inhibiting fibrosis using anti-pai-1 antibodies
|
WO2011143624A2
(en)
|
2010-05-14 |
2011-11-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Humanized and chimeric monoclonal antibodies to cd47
|
CN103079644B
(zh)
|
2010-06-11 |
2017-02-15 |
协和发酵麒麟株式会社 |
抗tim‑3抗体
|
JP2013532153A
(ja)
*
|
2010-06-18 |
2013-08-15 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
慢性免疫病に対する免疫治療のためのtim−3およびpd−1に対する二重特異性抗体
|
PE20140230A1
(es)
|
2010-08-20 |
2014-02-26 |
Novartis Ag |
Anticuerpos para el receptor del factor de crecimiento epidermico 3(her3)
|
PE20131403A1
(es)
|
2010-08-23 |
2014-01-10 |
Univ Texas |
Anticuerpos anti-ox40 y metodos de uso de los mismos
|
MY162737A
(en)
|
2010-09-09 |
2017-07-14 |
Pfizer |
4-1bb binding molecules
|
WO2012047583A2
(en)
*
|
2010-09-27 |
2012-04-12 |
Janssen Biotech, Inc. |
Antibodies binding human collagen ii
|
LT2635601T
(lt)
*
|
2010-11-04 |
2016-10-10 |
Boehringer Ingelheim International Gmbh |
Antikūnai prieš il-23
|
JP6167040B2
(ja)
|
2010-11-05 |
2017-07-19 |
ザイムワークス,インコーポレイテッド |
Fcドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
|
DE102010052101A1
(de)
|
2010-11-20 |
2012-05-24 |
Schaeffler Technologies Gmbh & Co. Kg |
Lagervorrichtung mit einem Fanglager
|
GB201020995D0
(en)
|
2010-12-10 |
2011-01-26 |
Bioinvent Int Ab |
Biological materials and uses thereof
|
CN104868975B
(zh)
|
2011-03-31 |
2019-07-19 |
华为技术有限公司 |
时分双工系统中子帧配置的方法、基站及用户设备
|
PT2691112T
(pt)
|
2011-03-31 |
2018-07-10 |
Merck Sharp & Dohme |
Formulações estáveis de anticorpos para o recetor pd-1 humano de morte programada e tratamentos relacionados
|
DK2699264T3
(en)
|
2011-04-20 |
2018-06-25 |
Medimmune Llc |
ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
|
WO2012145568A1
(en)
|
2011-04-21 |
2012-10-26 |
Albert Einstein College Of Medicine Of Yeshiva University |
Antibodies to human b7x for treatment of metastatic cancer
|
WO2012177624A2
(en)
|
2011-06-21 |
2012-12-27 |
The Johns Hopkins University |
Focused radiation for augmenting immune-based therapies against neoplasms
|
US8841418B2
(en)
|
2011-07-01 |
2014-09-23 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to TIM3
|
AU2012290121B2
(en)
|
2011-08-01 |
2015-11-26 |
Genentech, Inc. |
Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
|
KR101685262B1
(ko)
|
2011-08-23 |
2016-12-21 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
항-ox40 항체 및 이의 사용 방법
|
GB201115280D0
(en)
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
CA2846275C
(en)
|
2011-09-07 |
2019-07-16 |
Deutsches Krebsforschungszentrum |
Means and methods for treating and/or preventing natural ahr ligand-dependent cancer
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
WO2013054320A1
(en)
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
WO2013063702A1
(en)
|
2011-11-04 |
2013-05-10 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
UY34591A
(es)
|
2012-01-26 |
2013-09-02 |
Novartis Ag |
Compuestos de imidazopirrolidinona
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
US9340537B2
(en)
|
2012-05-15 |
2016-05-17 |
Novatis Ag |
Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
|
WO2013171641A1
(en)
|
2012-05-15 |
2013-11-21 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1
|
SG11201407190TA
(en)
|
2012-05-15 |
2014-12-30 |
Bristol Myers Squibb Co |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
ES2670601T3
(es)
|
2012-05-15 |
2018-05-31 |
Novartis Ag |
Derivados de benzamida para la inhibición de la actividad de ABL1, ABL2 y BCR-ABL1
|
US9278981B2
(en)
|
2012-05-15 |
2016-03-08 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
|
AU2013271515A1
(en)
|
2012-06-06 |
2015-01-15 |
Oncomed Pharmaceuticals, Inc. |
Binding agents that modulate the Hippo pathway and uses thereof
|
JO3300B1
(ar)
|
2012-06-06 |
2018-09-16 |
Novartis Ag |
مركبات وتركيبات لتعديل نشاط egfr
|
JP2015532587A
(ja)
*
|
2012-06-21 |
2015-11-12 |
コンピュゲン エルティーディー. |
Lsr抗体およびがんの治療のためのその使用
|
CA2916638C
(en)
|
2012-07-31 |
2021-01-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of the immune response
|
WO2014031718A1
(en)
|
2012-08-23 |
2014-02-27 |
Merck Sharp & Dohme Corp. |
Stable formulations of antibodies to tslp
|
JOP20200308A1
(ar)
*
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
US9676861B2
(en)
|
2012-10-30 |
2017-06-13 |
Apexigen, Inc. |
Anti-CD40 antibodies and methods of use
|
BR112015010477A2
(pt)
|
2012-11-08 |
2017-07-11 |
Novartis Ag |
combinação farmacêutica que compreende um inibidor b-raf e um inibidor de histona desacetilase e o uso dos mesmos no tratamento de doenças proliferativas
|
JP6423357B2
(ja)
|
2012-11-21 |
2018-11-14 |
ヤンセン バイオテツク,インコーポレーテツド |
二重特異性EGFR/c−Met抗体
|
BR112015012197A8
(pt)
|
2012-11-28 |
2019-10-01 |
Novartis Ag |
usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos
|
WO2014100483A1
(en)
|
2012-12-19 |
2014-06-26 |
Amplimmune, Inc. |
Anti-human b7-h4 antibodies and their uses
|
EP2943506B1
(en)
|
2013-01-10 |
2024-03-13 |
Genmab B.V. |
Human igg1 fc region variants and uses thereof
|
JO3519B1
(ar)
*
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
US9498532B2
(en)
|
2013-03-13 |
2016-11-22 |
Novartis Ag |
Antibody drug conjugates
|
WO2014159562A1
(en)
|
2013-03-14 |
2014-10-02 |
Bristol-Myers Squibb Company |
Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
|
US9242969B2
(en)
|
2013-03-14 |
2016-01-26 |
Novartis Ag |
Biaryl amide compounds as kinase inhibitors
|
PE20151939A1
(es)
|
2013-03-14 |
2016-01-08 |
Novartis Ag |
3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
|
CA2904337A1
(en)
|
2013-03-14 |
2014-10-02 |
Amgen Inc. |
Chrdl-1 antigen binding proteins and methods of treatment
|
KR20150127199A
(ko)
|
2013-03-14 |
2015-11-16 |
제넨테크, 인크. |
항-b7-h4 항체 및 면역접합체
|
EP2968985A2
(en)
*
|
2013-03-15 |
2016-01-20 |
Amgen, Inc. |
Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
|
BR112015022971B1
(pt)
|
2013-03-15 |
2022-05-17 |
Janssen Biologics B.V. |
Métodos de fabricação para controlar o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes
|
SG10201708048XA
(en)
|
2013-03-18 |
2017-10-30 |
Biocerox Prod Bv |
Humanized anti-cd134 (ox40) antibodies and uses thereof
|
LT2992017T
(lt)
*
|
2013-05-02 |
2021-02-25 |
Anaptysbio, Inc. |
Antikūnai nukreipti prieš programuotos žūties baltymą-1 (pd-1)
|
EP2994530A4
(en)
*
|
2013-05-10 |
2016-11-16 |
Whitehead Biomedical Inst |
PROTEIN MODIFICATION OF LIVING CELLS USING SORTASE
|
WO2014183885A1
(en)
|
2013-05-17 |
2014-11-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antagonist of the btla/hvem interaction for use in therapy
|
WO2014194302A2
(en)
|
2013-05-31 |
2014-12-04 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-1
|
CN104250302B
(zh)
|
2013-06-26 |
2017-11-14 |
上海君实生物医药科技股份有限公司 |
抗pd‑1抗体及其应用
|
CA2916681A1
(en)
|
2013-07-16 |
2015-01-22 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
|
CN105611947A
(zh)
|
2013-07-24 |
2016-05-25 |
丹娜法伯癌症研究院 |
用于中和半乳糖凝集素1(Gal1)的抗-Gal1单克隆抗体及其片段
|
DK3036258T3
(da)
|
2013-08-22 |
2023-10-09 |
Council Queensland Inst Medical Res |
Immunreceptormodulering til behandling af cancer og virusinfektioner
|
US10077305B2
(en)
|
2013-09-10 |
2018-09-18 |
Medimmune Limited |
Antibodies against PD-1 and uses thereof
|
CN112552401B
(zh)
|
2013-09-13 |
2023-08-25 |
广州百济神州生物制药有限公司 |
抗pd1抗体及其作为治疗剂与诊断剂的用途
|
CN104558177B
(zh)
|
2013-10-25 |
2020-02-18 |
苏州思坦维生物技术股份有限公司 |
拮抗抑制程序性死亡受体pd-1与其配体结合的单克隆抗体及其编码序列与用途
|
ME03527B
(me)
|
2013-12-12 |
2020-04-20 |
Shanghai hengrui pharmaceutical co ltd |
Pd-1 antitijelo, njegov fragment koji se vezuje na antigen, i njegova medicinska primjena
|
CN113402609B
(zh)
|
2013-12-20 |
2023-12-05 |
英特维特国际股份有限公司 |
具有经修饰的ch2-ch3序列的犬抗体
|
US9456612B2
(en)
|
2013-12-26 |
2016-10-04 |
Zimplistic Pte. Ltd. |
Dry flour dispensing apparatus and using the same for a food preparation appliance
|
CN103721255A
(zh)
*
|
2014-01-07 |
2014-04-16 |
苏州大学 |
共同阻断pd-1和tim-3信号通路在抗胃癌治疗中的用途
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
TWI681969B
(zh)
*
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
JP6868394B2
(ja)
|
2014-05-16 |
2021-05-12 |
ファイザー・インク |
二重特異性抗体
|
WO2015195163A1
(en)
|
2014-06-20 |
2015-12-23 |
R-Pharm Overseas, Inc. |
Pd-l1 antagonist fully human antibody
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
US10280223B2
(en)
|
2014-07-09 |
2019-05-07 |
Nippon Zenyaku Kogyo Co., Ltd. |
Anti-canine PD-1 antibody or anti-canine PD-L1 antibody
|
MX2017000985A
(es)
|
2014-07-22 |
2018-03-08 |
Cb Therapeutics Inc |
Anticuerpos anti-pd-1.
|
CA2957258C
(en)
|
2014-08-05 |
2023-11-07 |
MabQuest SA |
Immunological reagents
|
US9982052B2
(en)
|
2014-08-05 |
2018-05-29 |
MabQuest, SA |
Immunological reagents
|
GB201419084D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-PD-1 antibodies
|
WO2016077397A2
(en)
|
2014-11-11 |
2016-05-19 |
Sutro Biopharma, Inc. |
Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
US10239942B2
(en)
|
2014-12-22 |
2019-03-26 |
Pd-1 Acquisition Group, Llc |
Anti-PD-1 antibodies
|
CN105061597B
(zh)
|
2015-06-09 |
2016-04-27 |
北京东方百泰生物科技有限公司 |
一种抗pd-1的单克隆抗体及其获得方法
|
JP6974311B2
(ja)
|
2015-06-23 |
2021-12-01 |
メモリアル スローン ケタリング キャンサー センター |
新規pd−1免疫調節剤
|
US20170044265A1
(en)
*
|
2015-06-24 |
2017-02-16 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
DK3313441T3
(da)
*
|
2015-06-24 |
2024-04-15 |
Janssen Biotech Inc |
Immunmodulering og behandling af faste tumorer med antistoffer, der specifikt binder cd38
|
SG10201913303XA
(en)
|
2015-07-13 |
2020-03-30 |
Cytomx Therapeutics Inc |
Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
|
CN106699888B
(zh)
|
2015-07-28 |
2020-11-06 |
上海昀怡健康科技发展有限公司 |
一种pd-1抗体及其制备方法和应用
|
HRP20211645T1
(hr)
|
2015-07-30 |
2022-02-04 |
Macrogenics, Inc. |
Molekule za vezanje pd-1 i postupci za njihovu uporabu
|
WO2017024465A1
(en)
|
2015-08-10 |
2017-02-16 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibodies
|
WO2017024515A1
(en)
|
2015-08-11 |
2017-02-16 |
Wuxi Biologics (Cayman) Inc. |
Novel anti-pd-1 antibodies
|
PE20181322A1
(es)
|
2015-09-01 |
2018-08-14 |
Agenus Inc |
Anticuerpo anti-pd1 y sus metodos de uso
|
UA124259C2
(uk)
|
2015-09-28 |
2021-08-18 |
Сужоу Санкадіа Байофармасьютікалз Ко., Лтд. |
Фармацевтичне одержання стабільного анти-pd-1 антитіла та його застосування в медицині
|
AU2016332725A1
(en)
|
2015-09-29 |
2018-03-22 |
Celgene Corporation |
PD-1 binding proteins and methods of use thereof
|
EP3356416B1
(en)
|
2015-09-29 |
2021-03-24 |
Shanghai Zhangjiang Biotechnology Co., Ltd |
Pd-1 antibodies and uses thereof
|
CA3000564A1
(en)
|
2015-10-02 |
2017-04-06 |
Symphogen A/S |
Anti-pd-1 antibodies and compositions
|
EP3150636A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
CA2997799A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-pd1 antibodies and methods of use
|
HUE055407T2
(hu)
|
2015-10-02 |
2021-11-29 |
Hoffmann La Roche |
PD1-re és TIM3-ra specifikus bispecifikus antitestek
|
CN106632674B
(zh)
|
2015-10-30 |
2018-11-16 |
泽达生物医药有限公司 |
一种抗pd-1单克隆抗体、其药物组合物及其用途
|
BR112018008904A2
(pt)
|
2015-11-03 |
2018-11-27 |
Janssen Biotech Inc |
anticorpos que se ligam especificamente a tim-3 e seus usos
|
MX2018006243A
(es)
|
2015-11-18 |
2018-11-09 |
Merck Sharp & Dohme |
Proteinas de union a pd1/ctla4.
|
CN106699889A
(zh)
|
2015-11-18 |
2017-05-24 |
礼进生物医药科技(上海)有限公司 |
抗pd-1抗体及其治疗用途
|
JP6993699B2
(ja)
|
2016-01-11 |
2022-02-03 |
ウニヴェルズィテート・ツューリヒ |
ヒトインターロイキン-2に対する免疫刺激性ヒト化モノクローナル抗体及びその融合タンパク質
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
WO2018026248A1
(ko)
|
2016-08-05 |
2018-02-08 |
주식회사 와이바이오로직스 |
프로그램화된 세포 사멸 단백질(pd-1)에 대한 신규 항체 및 이의 용도
|
WO2018027524A1
(en)
|
2016-08-09 |
2018-02-15 |
Innovent Biologics (Suzhou) Co., Ltd. |
Pd-1 antibody formulation
|
CN106977602B
(zh)
|
2016-08-23 |
2018-09-25 |
中山康方生物医药有限公司 |
一种抗pd1单克隆抗体、其药物组合物及其用途
|
SI3512547T1
(sl)
|
2016-09-14 |
2021-01-29 |
Abbvie Biotherapeutics Inc. |
Anti-PD-1 protitelesa
|
AU2017328309B2
(en)
|
2016-09-14 |
2020-10-15 |
Beijing Hanmi Pharm. Co., Ltd. |
Antibody specifically binding to PD-1 and functional fragment thereof
|
MX2019003058A
(es)
|
2016-09-21 |
2019-11-28 |
Cstone Pharmaceuticals |
Anticuerpos monoclonales novedosos para muerte programada 1 (pd-1).
|
DE102017211373A1
(de)
|
2017-07-04 |
2019-01-10 |
Continental Automotive Gmbh |
Induktive Ladevorrichtung für ein elektrisch antreibbares Kraftfahrzeug und Betriebsverfahren für die Ladevorrichtung
|